SRR10900581
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.500
- MYC_TARGETS_V2+0.500
- UNFOLDED_PROTEIN_RESPONSE+0.500
- MTORC1_SIGNALING+0.400
- PROTEIN_SECRETION+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- DNA_REPAIR+0.300
- E2F_TARGETS+0.300
- G2M_CHECKPOINT+0.300
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INFLAMMATORY_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- HEDGEHOG_SIGNALING-0.300
- KRAS_SIGNALING_DN-0.300
- KRAS_SIGNALING_UP-0.300
- ANGIOGENESIS-0.200
- APICAL_JUNCTION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1011 | — | — | 0.894 |
| 2 | MNG534 | — | — | 0.893 |
| 3 | MNG1063 | — | — | 0.892 |
| 4 | MNG332 | — | — | 0.891 |
| 5 | SAMN03290931 | — | — | 0.881 |
| 6 | MDT-AP-2956 | Med | Medulloblastoma | 0.879 |
| 7 | BS_G23JJAZY | Supratentorial Ependymoma | — | 0.879 |
| 8 | MNG365 | — | — | 0.878 |
| 9 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.875 |
| 10 | TCGA-21-1075-01A-01R-0692-07 | — | cohortSQ2 | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.500 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |